biostudies-literatureUnknown53(3)Sachpekidis CDeutsches Krebsforschungszentrum (DKFZ)<h4>Purpose</h4>The clinical significance of medullary abnormalities in the appendicular skeleton detected by computed tomography (CT) in patients with multiple myeloma (MM) remains incompletely elucidated. This study aims to validate novel low-dose CT-based methods for quantifying myeloma bone marrow (BM) volume in the appendicular skeleton of MM patients undergoing [¹⁸F]FDG PET/CT.<h4>Materials and methods</h4>Seventy-two newly diagnosed, transplantation eligible MM patients enrolled in the randomised phase 3 GMMG-HD7 trial underwent whole-body [¹⁸F]FDG PET/CT prior to treatment and after induction therapy with either isatuximab plus lenalidomide, bortezomib, and dexamethasone or lenalidomide, bortezomib, and dexamethasone alone. Two CT-based methods using the MedicEuropean journal of nuclear medicine and molecular imaging1509-1520https://www.ebi.ac.uk/biostudies/studies/S-EPMC12860749biostudies-literatureValidation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [¹⁸F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.PMC12860749Hajiyianni MDimitrakopoulou-Strauss AJohn LWeinhold NEnqvist OPiller MSchlemmer HPSauer SKopp-Schneider AHundemer MDelorme SEdenbrandt LJauch AGoldschmidt HSachpekidis CGrozinger MMai EKMenis EJende JRaab MSBrobeil AfalseValidation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [¹⁸F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.<h4>Purpose</h4>The clinical significance of medullary abnormalities in the appendicular skeleton detected by computed tomography (CT) in patients with multiple myeloma (MM) remains incompletely elucidated. This study aims to validate novel low-dose CT-based methods for quantifying myeloma bone marrow (BM) volume in the appendicular skeleton of MM patients undergoing [¹⁸F]FDG PET/CT.<h4>Materials and methods</h4>Seventy-two newly diagnosed, transplantation eligible MM patients enrolled in the randomised phase 3 GMMG-HD7 trial underwent whole-body [¹⁸F]FDG PET/CT prior to treatment and after induction therapy with either isatuximab plus lenalidomide, bortezomib, and dexamethasone or lenalidomide, bortezomib, and dexamethasone alone. Two CT-based methods using the Medic2026-01-01T00:00:00Z2026 Feb2026-07-14T17:15:38.835Z2026-06-21T03:12:54.607ZS-EPMC128607494103207710.1007/s00259-025-07599-z